Onderzoeksgrade Coltuximab

Coltuximabravtansine (SAR3419) isanantibody-drugconjugate (ADC) targetingCD19createdbyconjugatingaderivativeofthepotentmicrotubule-actingcytotoxicagent, maytansine, toaversionoftheanti-CD19antibody, anti-B4, thatwashumanizedasanIgG1byvariabledomainresurfacing.Fourdifferentlinker-maytansinoidconstructsweresynthesized (average∼3.5maytansinoids/antibodyforeach) toevaluatetheimpactoflinker-payloaddesignontheactivityofthemaytansinoid-ADCstargetingCD19.Anti-CD19humanizedmonoclonalantibodyconjugatedtoDM4.

SAR3419, CAS:1269764-99-9

Mammalian Cells

CD19, DifferentiationantigenCD19, T-cellsurfaceantigenLeu-12, B-lymphocyteantigenCD19, B-lymphocytesurfaceantigenB4

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

1mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -166°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

Human

IgG1-kappa